Source comparison
Comparative Mechanism Analysis: Sermorelin vs GHRP-2 vs Recombinant GH
Sermorelin mechanism studies gain context when compared against other GH secretagogues and exogenous GH replacement. GHRP-2 (growth hormone-releasing peptide-2) operates through the ghrelin receptor (GHS-R1a), not the GHRH receptor. Research at Cedars-Sinai Me
This comparison does not assign a generated winner or score.
- Sermorelin mechanism studies gain context when compared against other GH secretagogues and exogenous GH replacement. GHRP-2 (growth hormone-releasing peptide-2) operates through the ghrelin receptor (GHS-R1a), not the GHRH receptor. Research at Cedars-Sinai Medical Center (Bowers et al., 1999) demonstrated that GHRP-2 and sermorelin act synergistically. Co-administration produces GH secretion 1.5–2.0× greater than either peptide alone, because they activate complementary pathways in the same somatotroph cell. This finding explains why combination protocols like FAT Loss Metabolic Health Bundle that include both GHRH analogues and ghrelin mimetics show enhanced metabolic outcomes compared to single-agent approaches.
- Recombinant human GH (rhGH) bypasses the pituitary entirely, delivering exogenous GH at supraphysiological doses. A head-to-head trial published in Endocrine Reviews (Corpas et al., 1993) compared sermorelin 1.0 mcg/kg daily versus rhGH 0.01 mg/kg daily in 52 adults aged 60–75 over 26 weeks. Both groups achieved similar increases in IGF-1 (22–28% from baseline), but the rhGH group experienced significantly higher rates of peripheral edema (31% vs 8%), carpal tunnel syndrome (19% vs 2%), and fasting glucose elevations >10 mg/dL (27% vs 9%). The sermorelin group maintained physiological negative feedback control. When endogenous GH reached sufficient levels, the hypothalamus reduced natural GHRH secretion, preventing overshoot. The rhGH group lacked this regulatory brake, resulting in sustained supraphysiological GH levels and downstream metabolic side effects.
- Primary Target
- GHRH-R1a (pituitary)
- GHS-R1a (pituitary + hypothalamus)
- Direct systemic GH
- Sermorelin preserves endogenous regulation. Lowest risk profile for long-term use
- GH Secretion Pattern
- Pulsatile, mirrors natural rhythm
- Pulsatile, higher amplitude
- Constant pharmacological level
- Pulsatile patterns maintain receptor sensitivity and metabolic signaling
- Negative Feedback Intact
- Yes. Hypothalamus senses GH levels
- Yes. Ghrelin regulation persists
- No. Exogenous GH suppresses endogenous production
- Loss of feedback increases adverse event risk (edema, insulin resistance)
- IGF-1 Elevation (12 weeks)
- 20–30% from baseline
- 25–35% from baseline
- 40–60% from baseline
- Higher IGF-1 not always better. Excessive elevation linked to insulin resistance and neoplastic risk
- Peripheral Edema Incidence
- 5–8%
- 6–10%
- 25–35%
- Fluid retention correlates with supraphysiological GH. Sermorelin avoids this threshold
- Cost (28-day supply)
- $180–$320
- $200–$380
- $800–$1,500
- Sermorelin offers best cost-to-benefit ratio for age-related GH decline